Is Oligonucleotide CMC Delaying Your Path to FDA Submission?
When your oligonucleotide program is on-track toward a New Drug Application (NDA), the last thing you need is CMC delays related to Regulatory Starting Materials (RSMs).
The problem:
Most vendors offer limited support, leaving you to manage the regulatory burden alone. The process is:
Slow
Highly technical
Prone to unanticipated hurdles
What If Your Supplier Was Already Ready?
With WuXi TIDES, the heavy lifting is already done.
Sponsors who choose WuXi TIDES for their oligonucleotide RSMs can avoid common documentation delays. Our regulatory-based strategy accelerates your timeline from development to NDA submission.
Inside the WuXi TIDES Product Manual, you’ll find information for submission-ready Drug Master Files (DMFs), fully prepared in advance, so you can stay focused on the big picture while we manage the details.
With WuXi TIDES as Your RSM Partner, You Can:
✔ Meet CMC requirements with confidence — and avoid last-minute delays
✔ Simplify regulatory documentation with pre-validated support
✔ Hit critical milestones on time with a clear, compliant path forward
What You’ll Find in the Product Manual
Impurity control and characterization strategy across the entire product line-up
Validated reproducibility that demonstrates consistency at commercial manufacturing scales
A better approach to oligonucleotide RSM, one that de-risks your regulatory CMC timeline
Ready to Accelerate Your Oligo Program?
Take the next step:
